Medication Interference with Pheochromocytoma Screening
Yes, buspirone can significantly interfere with pheochromocytoma screening and should be discontinued at least 48 hours before testing, while bupropion may also cause false-positive results and warrants caution.
Buspirone: Clear Interference
Buspirone hydrochloride directly interferes with urinary metanephrine/catecholamine assays 1. The FDA drug label explicitly states that buspirone "may interfere with the urinary metanephrine/catecholamine assay" and "has been mistakenly read as metanephrine during routine assay testing for pheochromocytoma, resulting in a false positive laboratory result" 1.
The drug label mandates discontinuation for at least 48 hours prior to urine collection for catecholamines 1. This is not optional—it is a specific requirement to avoid false-positive results that could lead to unnecessary imaging, invasive testing, or even inappropriate surgical intervention.
Recent case reports further support this concern, documenting severe hypertension with elevated plasma and urinary catecholamines in a patient using buspirone, which normalized after discontinuation 2.
Bupropion: Potential Interference
Bupropion is contraindicated in patients with pheochromocytoma due to seizure risk 3, but more relevant to screening, it has indirect norepinephrine agonist properties 4 that could theoretically elevate catecholamine measurements. While not explicitly listed in the major guidelines as an interfering medication, its pharmacodynamic profile warrants caution during biochemical testing.
Sertraline and Other SSRIs: Possible but Less Clear
The 2009 AACE/AAES guidelines mention that "tricyclic antidepressants, decongestants, amphetamines, reserpine, and phenoxybenzamine should be discontinued to eliminate the likelihood of a false-positive result" 55. While SSRIs like sertraline are not specifically listed, there is a case report of fluoxetine unmasking a pheochromocytoma through hypertensive paroxysm 6. The mechanism involves non-specific noradrenaline reuptake inhibition at higher doses combined with catecholamine release 6.
For sertraline at 25 mg daily (a low dose), the risk of interference is likely minimal, but if biochemical results are borderline or positive, consider the medication as a potential contributor.
Quetiapine: No Direct Interference
Quetiapine is not mentioned in any guideline as interfering with pheochromocytoma screening. At 25 mg nightly (a very low dose), it is unlikely to affect catecholamine or metanephrine measurements.
Clinical Approach
Before Screening:
- Discontinue buspirone for at least 48 hours before collecting 24-hour urine for metanephrines/catecholamines 1
- Consider holding bupropion if feasible, given its noradrenergic activity
- Continue sertraline and quetiapine at these low doses, but document their use
If Results Are Positive:
The 2020 Hypertension Canada guidelines emphasize that "potential false positive results should be considered in the setting of interfering drugs" 77. Specifically:
- If metanephrine elevations are less than twofold the upper limit of normal, strongly suspect medication interference
- Repeat testing after appropriate medication washout before proceeding to imaging 77
- Consider the clonidine suppression test for borderline elevations 778
Important Caveats:
Do not abruptly discontinue psychiatric medications without psychiatric consultation, especially bupropion (seizure risk with abrupt cessation) and sertraline (discontinuation syndrome). A 48-hour hold of buspirone is generally safe given its short half-life and anxiolytic (not antidepressant) indication, but coordinate with the prescribing psychiatrist.
The 2014 Endocrine Society guidelines note that medications interfering with catecholamine disposition can result in "mildly to markedly raised values" 8, and the clinical context (low pretest probability, mild elevations, atypical presentation) should guide interpretation 77.
Bottom line: Buspirone must be stopped before testing. Bupropion should be held if possible. Sertraline and quetiapine can likely continue, but document their use and interpret borderline results cautiously.